EP Patent

EP2873665A1 — Antiviral compounds

Assigned to Gilead Pharmasset LLC · Expires 2015-05-20 · 11y expired

What this patent protects

The invention provides a pharmaceutical composition comprising: (1) a compound of the formula: or a pharmaceutically acceptable salt thereof; (2) a NS5B polymerase inhibitor; and (3) a NS3 protease inhibitor; and relates to the use of (1), (2) and (3), in combination, in th…

USPTO Abstract

The invention provides a pharmaceutical composition comprising: (1) a compound of the formula: or a pharmaceutically acceptable salt thereof; (2) a NS5B polymerase inhibitor; and (3) a NS3 protease inhibitor; and relates to the use of (1), (2) and (3), in combination, in the prophylactic or therapeutic treatment of hepatitis C or a hepatitis C associated disorder.

Drugs covered by this patent

Patent Metadata

Patent number
EP2873665A1
Jurisdiction
EP
Classification
Expires
2015-05-20
Drug substance claim
No
Drug product claim
No
Assignee
Gilead Pharmasset LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.